JP2011506473A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011506473A5 JP2011506473A5 JP2010538181A JP2010538181A JP2011506473A5 JP 2011506473 A5 JP2011506473 A5 JP 2011506473A5 JP 2010538181 A JP2010538181 A JP 2010538181A JP 2010538181 A JP2010538181 A JP 2010538181A JP 2011506473 A5 JP2011506473 A5 JP 2011506473A5
- Authority
- JP
- Japan
- Prior art keywords
- kinase inhibitor
- use according
- alpha thymosin
- thymosin peptide
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1347607P | 2007-12-13 | 2007-12-13 | |
| PCT/US2008/086545 WO2009076587A1 (en) | 2007-12-13 | 2008-12-12 | Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011506473A JP2011506473A (ja) | 2011-03-03 |
| JP2011506473A5 true JP2011506473A5 (enExample) | 2012-02-02 |
Family
ID=40755899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010538181A Pending JP2011506473A (ja) | 2007-12-13 | 2008-12-12 | キナーゼ阻害剤と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100267637A1 (enExample) |
| EP (1) | EP2240194A4 (enExample) |
| JP (1) | JP2011506473A (enExample) |
| CN (1) | CN101945664A (enExample) |
| AR (1) | AR069769A1 (enExample) |
| AU (1) | AU2008335025A1 (enExample) |
| CA (1) | CA2708229A1 (enExample) |
| WO (1) | WO2009076587A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3943101A1 (en) * | 2014-10-21 | 2022-01-26 | SciClone Pharmaceuticals International Ltd. | Treatment of cancer with immune stimulator alpha thymosin peptide |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2604845A1 (de) * | 1976-02-07 | 1977-08-18 | Knoll Ag | Neue piperazinderivate |
| EP2633866A3 (en) * | 2003-10-17 | 2013-12-18 | Novo Nordisk A/S | Combination therapy |
| US20070292392A1 (en) * | 2006-06-15 | 2007-12-20 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma |
-
2008
- 2008-12-12 CN CN2008801268138A patent/CN101945664A/zh active Pending
- 2008-12-12 AU AU2008335025A patent/AU2008335025A1/en not_active Abandoned
- 2008-12-12 JP JP2010538181A patent/JP2011506473A/ja active Pending
- 2008-12-12 US US12/747,438 patent/US20100267637A1/en not_active Abandoned
- 2008-12-12 WO PCT/US2008/086545 patent/WO2009076587A1/en not_active Ceased
- 2008-12-12 EP EP08858909A patent/EP2240194A4/en not_active Withdrawn
- 2008-12-12 CA CA2708229A patent/CA2708229A1/en not_active Abandoned
- 2008-12-15 AR ARP080105451A patent/AR069769A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2530719T3 (es) | Formulaciones de oxicodona para ser administradas una vez al día | |
| NO20072325L (no) | Kombinasjonsterapi omfattende telmisartan og hydroklortiazid | |
| AU2003268144A8 (en) | Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist | |
| EA033415B1 (ru) | Способы лечения ожирения, применение ингибитора dpp-4 в этих способах и способ лечения пациентов, страдающих диабетом типа 2 | |
| BR0210971A (pt) | Formas inovadoras de dosagem de benzimidazol substituìdo e método para usar as mesmas | |
| EA200501420A1 (ru) | Устройство доставки для лекарственной и клеточной терапии | |
| JP2011506436A5 (enExample) | ||
| BR0315337A (pt) | Composto, formulação farmacêutica, e, método para tratar câncer | |
| AR053651A1 (es) | Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama | |
| EA200802412A1 (ru) | Терапевтические комбинации для сопровождающихся болью медицинских состояний | |
| CO6260019A2 (es) | Metodos para el tratamiento de desordenes gastrointestinales independientes de la ingesta de alimento | |
| CY1109191T1 (el) | Μια νεα χρηση της δεφεριπρονης | |
| JP2009215293A5 (enExample) | ||
| WO2010045417A3 (en) | Combination therapies for the treatment of obesity | |
| ES2570401T3 (es) | Métodos de tratamiento usando dosis únicas de oritavancina | |
| MX2009011900A (es) | Curacion de herida diabetica. | |
| JP2020500864A5 (enExample) | ||
| JP2012525358A5 (enExample) | ||
| AR065139A1 (es) | Medicamento para el tratamiento de la endometriosis | |
| JP2011506473A5 (enExample) | ||
| RU2002117537A (ru) | Способ лечения последствий тканевой гипоксии у пациентов в критическом состоянии | |
| DE602004030048D1 (de) | Ffizienz | |
| CA2595363A1 (en) | Methods and materials with trans-clomiphene for the treatment of male infertility | |
| AR039162A1 (es) | Formulaciones de venlafaxina de liberacion extendida | |
| Petek et al. | Pentadecapeptide BPC 157 attenuates gastric lesions induced by alloxan in rats and mice |